GlassScriptPhysician profile
Kyung J Chen
NPI 1700108925
$15,828.11
in general payments reported to CMS, 2019-2025
12 companies · $2,282 in 2025
The $2,282 reported for 2025 was more than what 81% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.23 · 2020: $526 · 2021: $412 · 2022: $3,061 · 2023: $6,763 · 2024: $2,746 · 2025: $2,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,626 · Travel and Lodging: $4,145 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,626.47 |
| Travel and Lodging | $4,145.07 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $12,803.95 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Boston Scientific Corporation | $1,935.07 | 2021-2025 | Intracept |
| Medtronic USA, INC. | $473.12 | 2020 | |
| Nevro Corp. | $179.97 | 2023 | Senza |
| Spr Therapeutics, INC | $93.00 | 2025 | Sprint Pns System |
| Nalu Medical, INC. | $83.24 | 2023-2024 | Nalu Neurostimulation System |
| Abbott Laboratories | $80.60 | 2021 | |
| Glaukos Corporation | $48.93 | 2025 | Idosetr, Istent Infinite |
| Ivantis, INC | $38.23 | 2019 | |
| Vertos Medical, INC. | $37.41 | 2020 | |
| Stimwave Technologies Incorporated | $34.78 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $19.81 | 2023 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyung Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.